Trial
NCT01873833
Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Southern California
Collaborators
National Cancer Institute (NCI)
Condition
HER2-positive Breast Cancer
Intervention
capecitabine
Why stopped
Insufficient accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-05